

Press Release

GlyTherix to Showcase its targeted radiotherapy technology at JPM Healthcare Week 2025 + Corporate Updates

Sydney, Australia – January 10, 2025 – GlyTherix, a leader in targeted radiotherapy, is set to present at two major events during JPM Healthcare Week in San Francisco, an annual gathering of top investors, biopharma executives, and industry leaders from the US, Europe, and Asia.

Key Presentations and Panels:

1. **Wuxi Aptec Global Forum (January 14, 2025):**

GlyTherix's CEO, Dr. Brad Walsh, will host an Executive Roundtable focused on the company's cutting-edge targeted radiotherapy technology, including its lead program targeting Glypican-1 and the potential opportunities it offers for advancing cancer treatment. This event will feature over 2,000 registrants, including global opinion leaders and emerging companies committed to accelerating breakthroughs in healthcare.

2. **Biotech Showcase 2025 (January 13-15, 2025):**

Dr. Walsh will also be speaking as a panelist at Biotech Showcase, a premier investor conference with over 400 presenting companies. The panel, "The Asia Pacific Region: Collaboration Opportunities & Scientific Engagement – Let's Discuss How to Build Partnerships," will explore the growing role of the Asia-Pacific region in biotech innovation. Other panelists include Alessandro Falcone, Regional Head of JLABS Singapore. This event is expected to attract thousands of registrants, including institutional investors, biopharmaceutical executives, and strategic partners.

Meetings with Potential Partners:

During JPM Healthcare Week, GlyTherix is scheduling a full slate of meetings with potential partners from major pharmaceutical companies and leading biotech firms, as well as accredited and institutional investors in the targeted radiotherapy sector.

Supply Chain Advancements:

GlyTherix has made significant progress in enhancing its supply chain infrastructure. The company has signed new agreements with **Eckert & Ziegler** and **Nusano** for isotope supply, bringing our total number of international supplier & manufacturing agreements to seven. These agreements will support GlyTherix' programs in the clinical development phase and through to market introduction of both beta and alpha emitters, critical components for GlyTherix's radiotherapy programs.

Congratulations to our Clinical Advisory Panel member Dr. Elcin Zan:

GlyTherix is pleased to congratulate **Clinical Advisory Panel member** Dr. Elcin Zan on her recent appointment as Chair of Nuclear Medicine at the **Cleveland Clinic**. This prestigious

achievement reflects Dr. Zan's exceptional contributions to the field of nuclear medicine and her ongoing commitment to advancing patient care.

Dr. Zan serves as a key advisor on GlyTherix's Clinical Advisory Panel, providing invaluable insights that continue to guide the company's development of targeted therapies. GlyTherix's innovative approach focuses on precision treatment for cancer, harnessing glypican-1-targeted therapies to improve patient outcomes and quality of life.

Please join us in congratulating Dr. Zan on this well-deserved recognition and celebrating her continued success.

About GlyTherix:

GlyTherix Ltd is an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumors. Miltuximab® specifically targets Glypican-1, a protein found in solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal and ovarian cancers, but is not present in normal, healthy tissue. The company has a strong proprietary and Intellectual property position covering both Miltuximab® and the Glypican-1 target. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. GlyTherix has completed a 'First-in-Human' trial of 12 patients using Miltuximab® with no drug-related adverse events. Miltuximab® will be used in a Phase Ib trial as an antibody theranostic. GlyTherix is interested in partnerships and collaborations with major pharmaceutical and biotech partners.

For media inquiries, please contact:

Dr. Brad Walsh, CEO

+61 413 231 296

brad.walsh@glytherix.com

www.glytherix.com

End of Release